Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CS-206 · 1 trial · 1 indication
Frequency and severity of adverse events(AEs）as assessed by CTCAE(Common Terminology Criteria for Adverse Events)v5.0
Incidence of transplant-related mortality(Transplant-related mortality events defined as deaths assessed by the investigator as potentially transplant-related)
Time to neutrophil engraftment is defined as first day of 3 consecutive measurements of absolute neutrophil count≥0.5×10\^9/L on three different days.
Time to platelet engraftment is defined as first day of 3 consecutive measurements of absolute platelet count≥20×10\^9/L on three different days and without platelet transfusion.
Free from severe vaso-occlusive crises (VOCs) for 12 consecutive months (VF12)
| Arm | Type | Description |
|---|---|---|
| CS-206 | EXPERIMENTAL | Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique |
| Name | Type | Description |
|---|---|---|
| CS-206 | GENETIC | Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique |
Inclusion Criteria: * Participants must be between 12 to 35 years old (inclusive). Participants or their legal guardians (for participants below 18 years old) must provide written informed consent before any study-related procedures. * Participants must have a Documented βS/βS, βS/β0 or βS/β+ genot...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Etavopivat Low dose |
| Novartis AG Sponsored ADR | NVS | 4 | PHASE3 | Crizanlizumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE3 | PCV21, 20vPCV |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | CTX001 |
| Agios Pharmaceuticals, Inc. | AGIO | 2 | PHASE2 | Mitapivat |
| Pfizer Inc. | PFE | 1 | PHASE2 | Osivelotor |
| Bristol-Myers Squibb Company | BMY | 1 | PHASE1 | BMS-986470, Famotidine, Pantoprazole |
| Fulcrum Therapeutics, Inc. | FULC | 1 | PHASE2 | Pociredir |
| Beam Therapeutics, Inc. | BEAM | 2 | PHASE1 | BEAM-101 |
| Editas Medicine, Inc. | EDIT | 2 | PHASE1 | EDIT-301 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-3405 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
CS-206 is an investigational gene therapy being developed for the treatment of Sickle Cell Disease. It is currently in early Phase 1 clinical development and has not been approved by regulatory authorities.
CS-206 is being developed by cbdMD, Inc., a company publicly traded under the ticker YCBD. The company is conducting clinical trials for this gene therapy candidate in Sickle Cell Disease.
CS-206 is in Phase 1 clinical development. Specifically, it is being studied in an early Phase 1 trial that is currently recruiting participants. The drug is investigational and has not been approved for commercial use.
CS-206 is being evaluated in a single clinical trial with the identifier NCT06565026, titled 'CS-206 in Patients With Sickle Cell Disease'. This early Phase 1 study is recruiting up to 5 participants in China and is not randomized or blinded.
Yes, CS-206 is a gene therapy. It is being studied as a potential treatment for Sickle Cell Disease, a hematologic condition. The ongoing clinical trial includes biomarker selection for participants.